Toxicity management in HCC treatment is discussed by medical experts.
The transcript is part of a medical expert discussion on the management of hepatocellular carcinoma (HCC) and its treatment strategies, focusing on the challenges of immunotherapy and the importance of education for both physicians and patients. The experts emphasize the need for vigilance as adverse events can occur unpredictably and stress the significance of recognizing early signs of potential complications, such as headaches and diarrhea. They discuss the importance of comprehensive patient support systems, including access to various specialists like ophthalmologists, rheumatologists, and dermatologists, as well as the role of nurse navigators and the implementation of referral systems to overcome barriers to care. The conversation highlights the complexity of managing treatment toxicities, especially in the context of the COVID era, where distinguishing between different symptoms can be challenging. The experts stress the significance of understanding the patient’s social background and support system, with a particular focus on optimizing care for vulnerable groups like the elderly or those with poor socioeconomic status. They emphasize the necessity of considering the individual patient’s quality of life and maintaining a patient-centered approach throughout the treatment process. The discussion underscores the importance of clinical pathways and the practical application of therapeutic approaches in real-world settings, addressing the gap between clinical trials and actual patient outcomes.
Overall, the conversation reflects the multidimensional nature of managing HCC, with a strong emphasis on patient education, comprehensive support systems, and a holistic understanding of the patient’s social and clinical context. The experts advocate for a personalized and proactive approach to managing treatment toxicities, ensuring optimal patient care and quality of life throughout the treatment journey.
Video synopsis is AI-generated and reviewed by AJMC editorial staff.
Persistence Pays Off With Zanubrutinib: A Challenging CLL Case With a Prior BTK Inhibitor Failure
May 10th 2024The case of a 77-year-old woman with a long chronic lymphocytic leukemia (CLL) history illustrates the novel use of zanubrutinib as a potential option for some patients who have failed first-generation Bruton tyrosine kinase (BTK) inhibitors and venetoclax.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
Persistence Pays Off With Zanubrutinib: A Challenging CLL Case With a Prior BTK Inhibitor Failure
May 10th 2024The case of a 77-year-old woman with a long chronic lymphocytic leukemia (CLL) history illustrates the novel use of zanubrutinib as a potential option for some patients who have failed first-generation Bruton tyrosine kinase (BTK) inhibitors and venetoclax.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
2 Commerce Drive
Cranbury, NJ 08512